BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
URL: http://jams.arakmu.ac.ir/article-1-4957-en.html
2- Hematology and Cancer Speciatist, Ayatollah Khansari Education and Treatment Center, School of Medicine, Arak University of medical Sciences, Arak, Iran , anoush_aa@yahoo.com
3- Hematology and Cancer Speciatist, Ayatollah Khansari Education and Treatment Center, School of Medicine, Arak University of medical Sciences, Arak, Iran
Background: Most of the current regimens in the treatment of multiple myeloma include thalidomide. Thalidomide is a modulator of the immune system and according to several studies, its main complication is thromboembolism. The aim of this study is to compare the thromboemboli prophylactic effect of aspirin and low dose warfarin in standard risk multiple myeloma patients that treated with regimens containing thalidomide.
Materials and Methods: In this double- blind clinical trial study, sixty-six patients with multiple myeloma under treatment with thalidomide-containing regimens with standard risk for thromboembolism who were admitted to Khansari hospital, entered the study according to inclusion and exclusion criteria. The incidence of thromboembolism in these patients was evaluated.
Results: Five patients in the warfarin group and 2 patients in the aspirin group had thromboemboli. Chi square analyses showed no significant difference between groups (p=0.635).
Conclusion: The results showed that both drugs are effective in preventing thromboembolism and can be used as a prophylactic treatment.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
